
FILE - This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. On Thursday, July 8, 2021, U.S. health regulators approved new prescribing instructions for the controversial Alzheimer's drug that are likely to limit use of the expensive therapy, which has faced an intense public backlash.
The Food and Drug Administration said the change is intended to address confusion among physicians and patients about who should get the drug, which has faced an intense public backlash since its approval last month.
The new drug label emphasizes that the drug, Aduhelm, is appropriate for patients with mild symptoms or early-stage Alzheimer's but has not been studied in patients with more advanced disease. That's a big change from the original FDA instructions, which said simply that the drug was approved for Alzheimer's disease in general.














Comment: With corruption like this in the healthcare industry, is it any wonder concerned citizens are sounding the alarm over the world's largest experimental coronavirus vaccine rollout? The Inanity of RNA Vaccines For COVID-19